{"id":"https://openalex.org/W7225327408","doi":"https://doi.org/10.1002/psp4.70358","title":"Drug\u2013Drug Interactions of Cenobamate With Medications: Dose\u2010Dependent Induction/Inhibition and Clinical Implications","display_name":"Drug\u2013Drug Interactions of Cenobamate With Medications: Dose\u2010Dependent Induction/Inhibition and Clinical Implications","publication_year":2026,"publication_date":"2026-11-01","ids":{"openalex":"https://openalex.org/W7225327408","doi":"https://doi.org/10.1002/psp4.70358","pmid":"https://pubmed.ncbi.nlm.nih.gov/42982766","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13736231"},"language":"en","primary_location":{"id":"doi:10.1002/psp4.70358","doi":"https://doi.org/10.1002/psp4.70358","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.70358","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.70358","source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics & Systems Pharmacology","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.70358","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5108683904","display_name":"Hiroyuki Ichida","orcid":"https://orcid.org/0009-0000-3920-2644","observed_orcids":["https://orcid.org/0009-0000-3920-2644"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Hiroyuki Ichida","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":"https://orcid.org/0009-0000-3920-2644","affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110532059","display_name":"Takaharu Nakao","orcid":"https://orcid.org/0009-0002-8406-5233","observed_orcids":["https://orcid.org/0009-0002-8406-5233"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takaharu Nakao","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":"https://orcid.org/0009-0002-8406-5233","affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160749105","display_name":"Takanori Mori","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Takanori Mori","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111295946","display_name":"Reina Makino","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Reina Makino","raw_affiliation_strings":["Medical Affairs Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020835682","display_name":"Marika Nakagawa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Marika Nakagawa","raw_affiliation_strings":["Medical Affairs Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Affairs Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010413244","display_name":"Kazuhiro Yoneda","orcid":"https://orcid.org/0009-0007-8618-6844","observed_orcids":["https://orcid.org/0009-0007-8618-6844"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Kazuhiro Yoneda","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":"https://orcid.org/0009-0007-8618-6844","affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004560940","display_name":"Yoshiyuki Yamaura","orcid":"https://orcid.org/0009-0004-7691-3874","observed_orcids":["https://orcid.org/0009-0004-7691-3874"]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yoshiyuki Yamaura","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":"https://orcid.org/0009-0004-7691-3874","affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5086720037","display_name":"Masanori Kuribayashi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210112155","display_name":"Ono Pharmaceutical (Japan)","ror":"https://ror.org/022jefx64","country_code":"JP","type":"company","lineage":["https://openalex.org/I4210112155"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Masanori Kuribayashi","raw_affiliation_strings":["Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Safety & Pharmacokinetic Research Ono Pharmaceutical Co., Ltd.  Osaka Japan","institution_ids":["https://openalex.org/I4210112155"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5010413244","https://openalex.org/A5108683904"],"corresponding_institution_ids":["https://openalex.org/I4210112155"],"apc_list":{"value":4140,"currency":"USD","value_usd":4140},"apc_paid":{"value":4140,"currency":"USD","value_usd":4140},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.83905532,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"15","issue":"11","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.9146000146865845,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.061400000005960464,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cenobamate","display_name":"cenobamate","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.996999979019165},{"id":"https://openalex.org/keywords/cytochrome-p450-induction","display_name":"cytochrome P450 induction","score":0.8939999938011169},{"id":"https://openalex.org/keywords/cyp2b6","display_name":"CYP2B6","score":0.9100000262260437},{"id":"https://openalex.org/keywords/cyp3a4","display_name":"CYP3A4","score":0.9990000128746033},{"id":"https://openalex.org/keywords/cyp2c19-inhibition","display_name":"CYP2C19 inhibition","score":0.9869999885559082},{"id":"https://openalex.org/keywords/physiologically-based-pharmacokinetic-model","display_name":"physiologically based pharmacokinetic modeling","score":0.8849999904632568},{"id":"https://openalex.org/keywords/epilepsy","display_name":"epilepsy","score":0.6240000128746033},{"id":"https://openalex.org/keywords/anticoagulants","display_name":"anticoagulants","score":0.9259999990463257},{"id":"https://openalex.org/keywords/antiplatelet-drugs","display_name":"antiplatelet agents","score":0.8840000033378601},{"id":"https://openalex.org/keywords/antihypertensive-drugs","display_name":"antihypertensive drugs","score":0.8899999856948853},{"id":"https://openalex.org/keywords/clopidogrel-metabolite","display_name":"clopidogrel metabolite","score":0.7950000166893005},{"id":"https://openalex.org/keywords/rivaroxaban","display_name":"rivaroxaban","score":0.8619999885559082}],"concepts":[{"id":"https://openalex.org/C185867374","wikidata":"https://www.wikidata.org/wiki/Q2562769","display_name":"Physiologically based pharmacokinetic modelling","level":3,"score":0.770799994468689},{"id":"https://openalex.org/C140840227","wikidata":"https://www.wikidata.org/wiki/Q3737532","display_name":"CYP2C19","level":4,"score":0.7020999789237976},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6620000004768372},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6550999879837036},{"id":"https://openalex.org/C109650736","wikidata":"https://www.wikidata.org/wiki/Q424440","display_name":"CYP3A4","level":4,"score":0.5479999780654907},{"id":"https://openalex.org/C2777498785","wikidata":"https://www.wikidata.org/wiki/Q422210","display_name":"Omeprazole","level":2,"score":0.5281000137329102},{"id":"https://openalex.org/C2992379925","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Pharmacokinetic interaction","level":4,"score":0.491100013256073},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.48910000920295715},{"id":"https://openalex.org/C2777477808","wikidata":"https://www.wikidata.org/wiki/Q407595","display_name":"Metabolite","level":2,"score":0.47909998893737793},{"id":"https://openalex.org/C149151106","wikidata":"https://www.wikidata.org/wiki/Q4677569","display_name":"Active metabolite","level":3,"score":0.46939998865127563},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4490000009536743},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.4375999867916107},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4050999879837036},{"id":"https://openalex.org/C97320921","wikidata":"https://www.wikidata.org/wiki/Q718753","display_name":"Drug interaction","level":3,"score":0.3937999904155731},{"id":"https://openalex.org/C50605568","wikidata":"https://www.wikidata.org/wiki/Q14912267","display_name":"CYP2B6","level":5,"score":0.3666999936103821},{"id":"https://openalex.org/C3020079912","wikidata":"https://www.wikidata.org/wiki/Q3918988","display_name":"Plasma concentration","level":2,"score":0.353300005197525},{"id":"https://openalex.org/C2776711289","wikidata":"https://www.wikidata.org/wiki/Q415122","display_name":"Fexofenadine","level":2,"score":0.34619998931884766},{"id":"https://openalex.org/C33664856","wikidata":"https://www.wikidata.org/wiki/Q3271142","display_name":"CYP2D6","level":4,"score":0.33980000019073486},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.3366999924182892},{"id":"https://openalex.org/C76318530","wikidata":"https://www.wikidata.org/wiki/Q16833590","display_name":"Area under the curve","level":2,"score":0.32429999113082886},{"id":"https://openalex.org/C2779908668","wikidata":"https://www.wikidata.org/wiki/Q834280","display_name":"Bupropion","level":3,"score":0.3098999857902527},{"id":"https://openalex.org/C2779066535","wikidata":"https://www.wikidata.org/wiki/Q39111","display_name":"Nifedipine","level":3,"score":0.30820000171661377},{"id":"https://openalex.org/C2778000748","wikidata":"https://www.wikidata.org/wiki/Q423071","display_name":"Midazolam","level":3,"score":0.29829999804496765},{"id":"https://openalex.org/C2779670145","wikidata":"https://www.wikidata.org/wiki/Q412515","display_name":"Bisoprolol","level":3,"score":0.2680000066757202},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.257999986410141},{"id":"https://openalex.org/C2780272996","wikidata":"https://www.wikidata.org/wiki/Q1261151","display_name":"Therapeutic drug monitoring","level":3,"score":0.2563999891281128},{"id":"https://openalex.org/C2780591200","wikidata":"https://www.wikidata.org/wiki/Q412534","display_name":"Carvedilol","level":3,"score":0.2531999945640564}],"mesh":[{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000925","descriptor_name":"Anticoagulants","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000959","descriptor_name":"Antihypertensive Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D002219","descriptor_name":"Carbamates","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D002219","descriptor_name":"Carbamates","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D002219","descriptor_name":"Carbamates","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002733","descriptor_name":"Chlorophenols","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008954","descriptor_name":"Models, Biological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D013777","descriptor_name":"Tetrazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D019540","descriptor_name":"Area Under Curve","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051544","descriptor_name":"Cytochrome P-450 CYP3A","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D065689","descriptor_name":"Cytochrome P-450 CYP2C19 Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D065689","descriptor_name":"Cytochrome P-450 CYP2C19 Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D065689","descriptor_name":"Cytochrome P-450 CYP2C19 Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D065702","descriptor_name":"Cytochrome P-450 CYP2B6","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D065731","descriptor_name":"Cytochrome P-450 CYP2C19","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/psp4.70358","doi":"https://doi.org/10.1002/psp4.70358","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.70358","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.70358","source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics & Systems Pharmacology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13736231","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13736231/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13736231/pdf/PSP4-15-e70358.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT Pharmacometrics Syst Pharmacol","raw_type":"Text"},{"id":"pmid:42982766","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42982766","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: pharmacometrics & systems pharmacology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:fa773b6ff3d741ad9ed521c9253fdb83","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/fa773b6ff3d741ad9ed521c9253fdb83","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"CPT: Pharmacometrics & Systems Pharmacology, Vol 15, Iss 11, Pp n/a-n/a (2026)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/psp4.70358","doi":"https://doi.org/10.1002/psp4.70358","is_oa":true,"landing_page_url":"https://doi.org/10.1002/psp4.70358","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/psp4.70358","source":{"id":"https://openalex.org/S4210231731","display_name":"CPT Pharmacometrics & Systems Pharmacology","issn_l":"2163-8306","issn":["2163-8306"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-1"],"host_organization":"https://openalex.org/P4310319908","host_organization_name":"Nature Portfolio","host_organization_lineage":["https://openalex.org/P4310319908","https://openalex.org/P4310319965"],"host_organization_lineage_names":["Nature Portfolio","Springer Nature"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"CPT: Pharmacometrics & Systems Pharmacology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320318186","display_name":"SK Life Science","ror":"https://ror.org/025t9c657"},{"id":"https://openalex.org/F4320327845","display_name":"Ono Pharmaceutical","ror":"https://ror.org/022jefx64"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7225327408.pdf","grobid_xml":"https://content.openalex.org/works/W7225327408.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W2042347442","https://openalex.org/W2049701261","https://openalex.org/W2089535392","https://openalex.org/W2123808537","https://openalex.org/W2140220482","https://openalex.org/W2146867319","https://openalex.org/W2149328140","https://openalex.org/W2151695776","https://openalex.org/W2491274253","https://openalex.org/W3008727277","https://openalex.org/W3011304812","https://openalex.org/W3016492152","https://openalex.org/W3092155009","https://openalex.org/W3109369097","https://openalex.org/W3161204932","https://openalex.org/W4200594888","https://openalex.org/W4294530663","https://openalex.org/W4381331530","https://openalex.org/W4383197015","https://openalex.org/W4389070464","https://openalex.org/W4400414058"],"related_works":["https://openalex.org/W4200594888","https://openalex.org/W7221191234","https://openalex.org/W4205162862","https://openalex.org/W7019049411","https://openalex.org/W4383197015","https://openalex.org/W4389460985","https://openalex.org/W3161204932","https://openalex.org/W7164154082","https://openalex.org/W3131951259","https://openalex.org/W4317567204"],"abstract_inverted_index":{"Cenobamate":[0],"causes":[1],"dose-dependent":[2,217],"cytochrome":[3],"P450":[4],"(CYP)2B6":[5],"and":[6,9,37,55,70,82,87,89,94,98,111,145,149,160,192,194,207,210],"CYP3A4":[7,208],"induction":[8],"CYP2C19":[10,213],"inhibition,":[11],"raising":[12],"concern":[13],"over":[14],"multi-pathway":[15],"drug-drug":[16],"interactions":[17],"(DDIs)":[18],"in":[19,133,219,238],"patients":[20],"with":[21,24,226],"epilepsy":[22],"treated":[23],"cardiovascular":[25],"co-medications.":[26],"We":[27],"developed":[28],"a":[29],"physiologically":[30],"based":[31],"pharmacokinetic":[32],"(PBPK)":[33],"model":[34,60],"for":[35,43,77,100,221,229],"cenobamate":[36,44,203],"verified":[38,59,232],"it":[39,211],"using":[40,47],"reported":[41],"DDIs":[42],"200":[45],"mg":[46],"three":[48],"probe":[49],"substrates:":[50],"bupropion":[51],"(CYP2B6),":[52],"midazolam":[53],"(CYP3A4),":[54],"omeprazole":[56],"(CYP2C19).":[57],"The":[58,172,231],"predicted":[61,130],"exposure":[62,119,138,173,220],"changes":[63,174],"(area":[64],"under":[65],"the":[66,125,154],"curve":[67],"ratio":[68,74,182],"[AUCR]":[69],"maximum":[71],"concentration":[72],"[Cmax]":[73],"with/without":[75],"cenobamate)":[76],"eight":[78,224],"drugs,":[79],"including":[80],"anticoagulants":[81,97],"antiplatelets":[83],"(apixaban,":[84],"cilostazol,":[85,117],"clopidogrel,":[86,136],"rivaroxaban),":[88],"antihypertensives":[90],"(amlodipine,":[91],"bisoprolol,":[92],"carvedilol,":[93],"nifedipine).":[95],"Regarding":[96],"antiplatelets,":[99],"apixaban,":[101],"AUCR/Cmax":[102,155,167,184],"ratios":[103,156,168,185],"were":[104,147,157,177],"0.78/0.92":[105],"(100":[106],"mg),":[107,110,114],"0.71/0.87":[108],"(200":[109],"0.63/0.83":[112],"(400":[113],"respectively.":[115,151],"For":[116,135,152],"parent":[118,137],"decreased":[120,148,166,196],"(0.67/0.85,":[121],"0.55/0.77,":[122],"0.45/0.70),":[123],"while":[124],"active":[126],"metabolite":[127],"OPC-13015":[128],"was":[129,139],"to":[131,189,215],"increase":[132],"Cmax.":[134],"unchanged,":[140],"but":[141],"formation":[142],"of":[143,175,186,223],"2-oxo-clopidogrel":[144],"clopidogrel-H4":[146],"increased,":[150],"rivaroxaban,":[153],"0.78/0.90,":[158],"0.69/0.85,":[159],"0.61/0.80.":[161],"Among":[162],"antihypertensives,":[163],"amlodipine":[164],"showed":[165],"(0.57/0.66,":[169],"0.45/0.55,":[170],"0.37/0.47).":[171],"bisoprolol":[176],"minor":[178],"(AUCR":[179],"0.84-0.92,":[180],"Cmax":[181],"0.95-0.98);":[183],"carvedilol":[187],"fell":[188],"0.73/0.80,":[190],"0.63/0.71,":[191],"0.55/0.64;":[193],"nifedipine":[195],"markedly":[197],"(0.41/0.54,":[198],"0.29/0.41,":[199],"0.21/0.32).":[200],"In":[201],"conclusion,":[202],"induced":[204],"CYP2B6":[205],"weakly":[206],"moderately,":[209],"inhibited":[212],"moderately":[214],"drive":[216],"decreases":[218],"seven":[222],"drugs":[225],"minimal":[227],"change":[228],"bisoprolol.":[230],"PBPK":[233],"framework":[234],"enables":[235],"risk":[236],"assessment":[237],"scenarios":[239],"not":[240],"yet":[241],"clinically":[242],"tested.":[243]},"counts_by_year":[],"updated_date":"2026-11-09T13:22:03.289127","created_date":"2026-11-06T00:00:00"}